Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | BCHE | P06276 | 1/20 | 0.51 |
| ▸ | CD274 | Q9NZQ7 | 2/20 | 0.49 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.49 |
| ▸ | MITF | O75030 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL178900 | 0.86 | MEN1 (0.59) | MEN1KMT2ABCHEOPRK1ALDH1A1 | |
| SCHEMBL11102216 | 0.84 | MEN1 (0.59) | MEN1KMT2ABCHEOPRK1MITF | |
| SCHEMBL178869 | 0.83 | MEN1 (0.55) | MEN1KMT2A | |
| SCHEMBL178870 | 0.83 | MEN1 (0.55) | MEN1KMT2A | |
| SCHEMBL7148390 | 0.81 | ADRB3 (0.56) | — | |
| SCHEMBL7148387 | 0.81 | ADRB3 (0.56) | — | |
| SCHEMBL10070262 | 0.81 | MEN1 (0.53) | MEN1KMT2ABCHECD274 | |
| SCHEMBL10070263 | 0.80 | BCHE (0.58) | MEN1KMT2ABCHECD274ALDH1A1 | |
| SCHEMBL10070264 | 0.80 | BCHE (0.58) | MEN1KMT2ABCHECD274ALDH1A1 | |
| SCHEMBL8905807 | 0.79 | OPRK1 (0.48) | MEN1KMT2ACD274OPRK1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120058133-A1 | INHIBITION OF TRNA SYNTHETASES AND THERAPEUTIC APPLICATIONS THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2012-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120058133-A1 | INHIBITION OF TRNA SYNTHETASES AND THERAPEUTIC APPLICATIONS THEREOF | AARS1, GARS1, TRMT1 | MEN1 4664/4885KMT2A 2778/4885BCHE 4506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.